Morgan Stanley

Key Information Document

Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

You are about to purchase a product that is not simple and may be difficult to understand.

Product

Product name	Autocallable Barrier Note Linked to a Basket of Indices
Product identifier	ISIN: XS1919505427
PRIIP manufacturer	Morgan Stanley & Co. International plc (www.sp.morganstanley.com/eu). The product issuer is Morgan Stanley BV with a guarantee by Morgan Stanley.
Telephone number	+44-20-7425-8000
Competent authority of the PRIIP manufacturer	Authorised by the U.K. Prudential Regulation Authority and regulated by the U.K. Financial Conduct Authority and U.K. Prudential Regulation Authority
Date and time of production	16 January 2019 09:53 London local time

1. What is this product?

Type

English law governed notes

Objectives

(Terms that appear in **bold** in this section are described in more detail in the table(s) below.)

The product is designed to provide a return in the form of a cash payment on termination of the product. The timing and amount of this payment will depend on the performance of the **underlyings**. The product has a fixed term and will terminate on the **maturity date**, unless terminated early. If, at maturity, the **worst performing underlying** has fallen below its **barrier level**, the product may return less than the **product notional amount** or even zero.

Early termination following an autocall: The product will terminate prior to the **maturity date** if, on any **autocall observation date**, the **reference level** of the **worst performing underlying** is at or above its **autocall barrier level**. On any such early termination, you will on the immediately following **autocall payment date** receive a cash payment equal to the applicable **autocall payment**. The relevant dates and **autocall payments** are shown in the table(s) below.

Autocall observation dates	*Autocall payment dates*
26 February 2020	11 March 2020
26 August 2020	10 September 2020
26 February 2021	12 March 2021
26 August 2021	10 September 2021
28 February 2022	14 March 2022
26 August 2022	12 September 2022
27 February 2023	13 March 2023
29 August 2023	13 September 2023
26 February 2024	11 March 2024
27 August 2024	11 September 2024
26 February 2025	Maturity date

Termination on the maturity date: If the product has not terminated early, on the **maturity date** you will receive:

1. if the **final reference level** of the **worst performing underlying** is at or above its **barrier level**, a cash payment equal to USD 1,000.00; or
2. if the **final reference level** of the **worst performing underlying** is below its **barrier level**, a cash payment directly linked to the performance of the **worst performing underlying**. The cash payment will equal (i) the **product notional amount** multiplied by (ii) (A) the **final reference level** of the **worst performing underlying** divided by (B) its **strike level**.

Under the product terms, certain dates specified above and below will be adjusted if the respective date is either not a business day or not a trading day (as applicable). Any adjustments may affect the return, if any, you receive.

The product terms also provide that if certain exceptional events occur (1) adjustments may be made to the product and/or (2) the product issuer may terminate the product early. These events are specified in the product terms and principally relate to the **underlyings**, the product and the product issuer. The return (if any) you receive on such early termination is likely to be different from the scenarios described above and may be less than the amount you invested.

Underlyings	S&P 500 INDEX (SPX; ISIN: US78378X1072; Bloomberg: SPX Index), EURO STOXX 50 INDEX (SX5E; ISIN: EU0009658145; Bloomberg: SX5E Index) and FTSE 100 INDEX (UKX; ISIN: GB0001383545; Bloomberg: UKX Index)	**Reference level**	The closing level of an **underlying** as per the relevant **reference source**
Asset class	Equity	**Reference sources**	• SPX: Standard & Poor's • SX5E: STOXX • UKX: FTSE
Product notional amount	USD 1,000.00	**Final reference level**	The **reference level** on the **final valuation date**
Issue price	100.00% of the **product notional amount**	**Initial valuation date**	26 February 2019
Product currency	U.S. Dollar (USD)	**Final valuation date**	26 February 2025
Underlying currencies	• SPX: USD	**Maturity date / term**	12 March 2025

	• SX5E: Euro (EUR) • UKX: Pound Sterling (GBP)		
Issue date	12 March 2019	**Autocall barrier level**	100.00% of the **initial reference level**
Initial reference level	The **reference level** on the **initial valuation date**	**Autocall payments**	On the first **autocall payment date**, USD 1,150.00; thereafter increasing by USD 75.00 on each subsequent **autocall payment date**
Strike level	100.00% of the **initial reference level**	**Worst performing underlying**	For purposes of the payment at maturity: The **underlying** with the worst performance between the **initial reference level** and the **final reference level** For all other purposes: For a given date, the **underlying** with the worst performance between the **initial reference level** and the relevant **reference level**
Barrier level	60.00% of the **initial reference level**		

Intended retail investor

The product is intended to be offered to retail investors who fulfil all of the criteria below:

1. they have the ability to make an informed investment decision through sufficient knowledge and understanding of the product and its specific risks and rewards, with experience of investing in and/or holding a number of similar products providing a similar market exposure, either independently or through professional advice;
2. they expect the movement in the underlying to perform in a way that generates a favourable return, have an investment horizon of the recommended holding period specified below and understand that the product may terminate early;
3. they accept the risk that the issuer or guarantor could fail to pay or perform its obligations under the product and they are able to bear a total loss of their investment; and
4. they are willing to accept a level of risk to achieve potential returns that is consistent with the summary risk indicator shown below.

The product is not intended to be offered to retail clients who do not fulfil these criteria.

2. What are the risks and what could I get in return?

Risk indicator



Lower risk **Higher risk**



The risk indicator assumes you keep the product for 6 years. The actual risk can vary significantly if you cash in at an early stage and you may get back less. You may not be able to sell your product easily or may have to sell at a price that significantly impacts on how much you get back.

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.

We have classified this product as 5 out of 7, which is a medium-high risk class. This rates the potential losses from future performance at a medium-high level, and poor market conditions are unlikely to impact our capacity to pay you.

Be aware of currency risk: If the currency of your account is different to the currency of this product, you will be exposed to the risk of suffering a loss as a result of the conversion of the currency of the product into the account currency. This risk is not considered in the indicator shown above.

This product does not include any protection from future market performance so you could lose some or all of your investment.

For detailed information about all risks relating to the product please refer to the risk sections of the prospectus and any supplements thereto as specified in the section "7. Other relevant information" below.

Performance scenarios

Investment: USD 10,000

Scenarios		*1 year*	*4 years*	*6 years (Recommended holding period)*
Stress scenario	**What you might get back after costs**	USD 5,126.47	USD 4,326.71	USD 2,697.19
	Average return each year	-48.74%	-24.37%	-19.62%
Unfavourable scenario	**What you might get back after costs**	USD 8,542.34	USD 8,001.33	USD 5,417.11
	Average return each year	-14.58%	-7.16%	-9.71%
Moderate scenario	**What you might get back after costs**	USD 10,938.59	USD 11,762.50	USD 11,500.00
	Average return each year	9.39%	5.56%	2.36%
Favourable scenario	**What you might get back after costs**	USD 11,523.09	USD 12,536.82	USD 14,500.00
	Average return each year	15.23%	7.83%	6.39%

This table shows the money you could get back over the next 6 years as well as the annualized return calculated on a compounded basis under different scenarios, assuming that you invest USD 10,000.

The scenarios shown illustrate how your investment could perform. You can compare them with the scenarios of other products. The scenarios presented are an estimate of future performance based on evidence from the past on how the value of this investment varies, and are not an exact indicator. What you get will vary depending on how the market performs and how long you keep the product. The stress scenario shows what you might get back in extreme market circumstances, and it does not take into account the situation where we are not able to pay you. In addition, you should note that the results shown for the intermediate holding periods do not reflect estimates of the product's future value. You should therefore not base your investment decision on the results shown for these interim holding periods.

DocID: 7176e693-fe94-421c-8759-2c4dd01ed9dc

The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

3. What happens if Morgan Stanley BV is unable to pay out?

You are exposed to the risk that the issuer or guarantor might be unable to meet its obligations in connection with the product for instance in the event of bankruptcy or an official directive for resolution action. This may materially adversely affect the value of the product and could lead to you losing some or all of your investment in the product. The product is not a deposit and as such is not covered by any deposit protection scheme.

4. What are the costs?

The Reduction in Yield (RIY) shows what impact the total costs you pay will have on the investment return you might get. The total costs take into account one-off, ongoing and incidental costs.

The amounts shown here are the cumulative costs of the product itself, for three different holding periods. They include potential early exit penalties. The figures assume you invest USD 10,000. The figures are estimates and may change in the future.

Costs over time

Investment: USD 10,000			
Scenarios	***If you cash in after 1 year***	***If you cash in after 4 years***	***If you cash in at the end of the recommended holding period***
Total costs	USD 804.39477	USD 864.98256	USD 845.67901
Impact on return (RIY) per year	8.04395%	2.52658%	1.21771%

The costs shown in the table above represent how much the expected costs of the product would affect your return, assuming the product performs in line with the moderate performance scenario.

The person selling you or advising you about this product may charge you other costs. If so, this person will provide you with information about these costs, and show you the impact that all costs will have on your investment over time.

Composition of costs

The table below shows:

- The impact each year of the different types of costs on the investment return you might get at the end of the recommended holding period.
- The meaning of the different cost categories.

The table shows the impact on return per year.			
One-off costs	*Entry costs*	1.21771%	The impact of the costs already included in the price.
	Exit costs	0.00%	The impact of the costs of exiting your investment when it matures.
Ongoing costs	*Other ongoing costs*	0.00%	The impact of the costs that we take each year for managing your investments.

The costs shown in the table above represent the split of the reduction in yield shown in the costs over time table at the end of the recommended holding period. The split of the actual estimated costs of the product as a percentage of the **product notional amount** is estimated to be as follows: entry costs: 6.85% and exit costs: 0.00%.

5. How long should I hold it and can I take money out early?

Recommended holding period: 6 years

The product aims to provide you with the return described under “1. What is this product?” above. However, this only applies if the product is held to maturity. It is therefore recommended that the product is held until 12 March 2025 (maturity).

The product does not guarantee the possibility to disinvest other than by selling the product either (1) through the exchange (if the product is listed) or (2) off-exchange, where an offer for such product exists. No fees or penalties will be charged by the issuer for any such transaction, however an execution fee might be chargeable by your broker if applicable. By selling the product before its maturity, you may receive back less than you would have received if you had kept the product until maturity.

Exchange listing	Irish Stock Exchange - Global Exchange Market	**Price quotation**	Percentage
Smallest tradable unit	USD 1,000.00		

In volatile or unusual market conditions, or in the event of technical faults/disruptions, the purchase and/or sale of the product can be temporarily hindered and/or suspended and may not be possible at all.

6. How can I complain?

Any complaint regarding the conduct of the person advising on, or selling, the product can be submitted directly to that person.

Any complaint regarding the product or the conduct of the manufacturer of this product can be submitted in writing at the following address: 25 Cabot Square, London E14 4QA, United Kingdom, by email to: rspcomplaints@morganstanley.com. Please see also www.sp.morganstanley.com/eu. Complaints should include the name of the product, ISIN and reason for the complaint.

7. Other relevant information

The information contained in this Key Information Document does not constitute a recommendation to buy or sell the product and is no substitute for individual consultation with your bank or advisor.

The product is not in any way sponsored, sold or promoted by any relevant stock market, relevant index, related exchange or index sponsor. Further information in respect of the index is available from the index administrator.

The offering of this product has not been registered under the U.S. Securities Act of 1933. This product may not be offered or sold, directly or indirectly, in the United States of America or to U.S. persons. The term "U.S. person" is defined in Regulation S under the U.S. Securities Act of 1933, as amended.

Any additional documentation in relation to the product, in particular, the issuance programme documentation, any supplements thereto and the product terms are available free of charge from 25 Cabot Square, London E14 4QA, United Kingdom.

DocID: 7176e693-fe94-421c-8759-2c4dd01ed9dc